GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Additional Paid-In Capital

Noxopharm (ASX:NOX) Additional Paid-In Capital : A$0.00 Mil(As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Additional Paid-In Capital?



Noxopharm Additional Paid-In Capital Historical Data

The historical data trend for Noxopharm's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Additional Paid-In Capital Chart

Noxopharm Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Additional Paid-In Capital
Get a 7-Day Free Trial - - - - -

Noxopharm Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Noxopharm Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Noxopharm Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Noxopharm's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Noxopharm (ASX:NOX) Business Description

Industry
Traded in Other Exchanges
Address
60 Linksley Ave, Glenhaven, NSW, AUS, 2156
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines